Nxera To Receive $4.8M From Centessa For Progress On OX2R Agonist ORX142 Targeting Brain Disorders
Nxera to receive $4.8M in milestones as Centessa advances OX2R agonist ORX142 into Phase 1 for neurodegenerative disorders.
Nxera Pharma has announced it will receive $4.8 million in milestone payments from its partner, Centessa Pharmaceuticals. These payments follow Centessa’s initiation of clinical development for ORX142, a highly selective orexin receptor 2 (OX2R) agonist, after the U.S. FDA cleared its Investigational New Drug (IND) application for a Phase 1 trial in healthy volunteers.
ORX142 is being developed to treat neurological and neurodegenerative disorders and marks Centessa’s second OX2R agonist program. The Phase 1 study will focus on evaluating its safety and pharmacological profile in humans for the first time.
As part of the financial arrangement, Nxera will recognize $1.8 million in revenue for Q2 2025 for the IND clearance and $3.0 million in Q3 2025 upon clinical trial initiation. These milestone revenues highlight Nxera's successful ongoing partnership with Centessa and its presence in advancing neurotherapeutic innovation.
Reporting on the science, business and regulation shaping the pharmaceutical industry.
Altro da Pharma News
Tutti gli articoli →
Medicus Pharma presenta all’FDA il protocollo di fase 2b/3 per Teverelix
Fresenius Kabi Riceve una Lettera di Richiamo dalla FDA dopo Fallimenti nelle Indagini sul Processo Asettico presso lo Stabilimento di Melrose Park
Discussion